Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 11:12:635371.
doi: 10.3389/fimmu.2021.635371. eCollection 2021.

Lack of Effectiveness of Repurposed Drugs for COVID-19 Treatment

Miguel Angel Martinez  1
Affiliations

Lack of Effectiveness of Repurposed Drugs for COVID-19 Treatment

Miguel Angel Martinez. Front Immunol. .
No abstract available

Keywords: COVID-19; HCV; HIV; repurposed drugs; treatment efficacy.

PubMed Disclaimer

Conflict of interest statement

The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Martinez MA. Compounds with therapeutic potential against novel respiratory 2019 coronavirus. Antimicrob Agents Chemother. (2020) 64:e00399–20. 10.1128/AAC.00399-20 - DOI - PMC - PubMed
    1. Martinez MA. Clinical trials of repurposed antivirals for SARS-CoV-2. Antimicrob Agents Chemother. (2020) 64:e01101–20. 10.1128/AAC.01101-20 - DOI - PMC - PubMed
    1. Doi Y, Hibino M, Hase R, Yamamoto M, Kasamatsu Y, Hirose M, et al. . A prospective, randomized, open-label trial of early versus late favipiravir in hospitalized patients with COVID-19. Antimicrob Agents Chemother. (2020) 64:e01897–20. 10.1128/AAC.01897-20 - DOI - PMC - PubMed
    1. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. . A Trial of Lopinavir–Ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. (2020) 382:1787–99. 10.1056/NEJMoa2001282 - DOI - PMC - PubMed
    1. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. . Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. (2020) 395:1569–78. 10.1016/S0140-6736(20)31022-9 - DOI - PMC - PubMed

Substances